Clinical Trials
33 trialsNovel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
National Institutes of Health Clinical Center (CC)
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Radiation Therapy in Treating Patients Who Are Undergoing Surgery to Remove a Metastatic Brain Tumor
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
National Cancer Institute (NCI)
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
National Cancer Institute (NCI)
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
National Cancer Institute (NCI)
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
National Cancer Institute (NCI)
Irinotecan in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Procarbazine in Treating Patients With Recurrent Brain Tumor
National Cancer Institute (NCI)
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
National Cancer Institute (NCI)
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
National Institutes of Health Clinical Center (CC)